Genetic diversity of three surface protein genes in Plasmodium malariae from three Asian countries

Abstract

BackgroundGenetic diversity of the three important antigenic proteins, namely thrombospondin-related anonymous protein (TRAP), apical membrane antigen 1 (AMA1), and 6-cysteine protein (P48/45), all of which are found in various developmental stages of Plasmodium parasites is crucial for targeted vaccine development. While studies related to the genetic diversity of these proteins are available for Plasmodium falciparum and Plasmodium vivax, barely enough information exists regarding Plasmodium malariae. The present study aims to demonstrate the genetic variations existing among these three genes in P. malariae by analysing their diversity at nucleotide and protein levels.MethodsThree surface protein genes were isolated from 45 samples collected in Thailand (N = 33), Myanmar (N = 8), and Lao PDR (N = 4), using conventional polymerase chain reaction (PCR) assay. Then, the PCR products were sequenced and analysed using BioEdit, MEGA6, and DnaSP programs.ResultsThe average pairwise nucleotide diversities (π) of P. malariae trap, ama1, and p48/45 were 0.00169, 0.00413, and 0.00029, respectively. The haplotype diversities (Hd) of P. malariae trap, ama1, and p48/45 were 0.919, 0.946, and 0.130, respectively. Most of the nucleotide substitutions were non-synonymous, which indicated that the genetic variations of these genes were maintained by positive diversifying selection, thus, suggesting their role as a potential target of protective immune response. Amino acid substitutions of P. malariae TRAP, AMA1, and P48/45 could be categorized to 17, 20, and 2 unique amino-acid variants, respectively. For further vaccine development, carboxyl terminal of P48/45 would be a good candidate according to conserved amino acid at low genetic diversity (π = 0.2–0.3).ConclusionsHigh mutational diversity was observed in P. malariae trap and ama1 as compared to p48/45 in P. malariae samples isolated from Thailand, Myanmar, and Lao PDR. Taken together, these results suggest that P48/45 might be a good vaccine candidate against P. malariae infection because of its sufficiently low genetic diversity and highly conserved amino acids especially on the carboxyl end.Electronic supplementary materialThe online version of this article (10.1186/s12936-018-2176-x) contains supplementary material, which is available to authorized users.

Genetic polymorphisms in malaria vaccine candidate Plasmodium falciparum reticulocyte-binding protein homologue-5 among populations in Lagos, Nigeria

“…The field efficacies of vaccine against P. falciparum, the deadliest species of malaria parasite, have been significantly hampered by genetic polymorphisms in candidate antigens. These polymorphisms alter the epitope expression leading to loss of vaccine efficacy [3], hence vaccines designed with sequence compositions identical to the infecting parasites can offer protection against infections by such parasites [4,5].…”

Population genetic structure of domain I of apical membrane antigen-1 in Plasmodium falciparum isolates from Hazara division of Pakistan

“…However, the genetic polymorphisms in these parasite proteins create hurdles in development of effective vaccines [ 7 ]. These polymorphisms change the critical epitopes expression and eventually reduce or cause complete loss of vaccine efficacy [ 8 ]. Therefore, extensive evaluation of genetic variants in these vaccine candidate antigenic proteins in P. falciparum populations from malaria endemic regions is primarily important for an effective and enduring vaccine development.…”

Single-nucleotide polymorphism characterization of gametocyte development 1 gene in Plasmodium falciparum isolates from Baringo, Uasin Gishu, and Nandi Counties, Kenya

“…The change in amino acid from aspartate (D) to glutamate (E) is conservative because both amino acids have the same properties due to their negatively charged side chains. Conservative amino acids reduce the genetic diversity of a protein, making it a potential target for vaccine development (Srisutham et al, 2018).…”